Ovarian cancer combo trial halted early
Disease control
Terminated
This study tested a new drug, CRLX101, combined with standard chemotherapy (paclitaxel) in 30 women with ovarian cancer that came back or didn't go away. The goal was to find the safest dose and see if the combination helped shrink tumors. The trial was terminated early, so resul…
Phase: PHASE1, PHASE2 • Sponsor: NewLink Genetics Corporation • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC